Literature DB >> 11095864

Drug Interactions with Antiretrovirals.

.   

Abstract

The rapid development of new antiretroviral drugs, along with the evolution in clinical practice toward the recommended use of three- to four-drug combination regimens for achieving optimal suppression of viral replication, has brought the relevance of drug-drug interactions to the forefront of care for HIV-infected individuals. However, the routine clinical interpretation of drug interactions is complicated by our expanding knowledge of the physiologic mechanisms underlying pharmacokinetic interactions, particularly as they relate to drug transport and distribution (eg, P-glycoprotein) and biotransformation (hepatic cytochrome p450 monooxygenase induction and inhibition).

Entities:  

Year:  2000        PMID: 11095864     DOI: 10.1007/s11908-000-0043-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  54 in total

1.  Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro.

Authors:  S Kewn; P G Hoggard; J S Henry-Mowatt; G J Veal; S D Sales; M G Barry; D J Back
Journal:  AIDS Res Hum Retroviruses       Date:  1999-06-10       Impact factor: 2.205

Review 2.  Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Infect Dis       Date:  1999-03       Impact factor: 9.079

Review 3.  Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems.

Authors:  E G Schuetz; A H Schinkel
Journal:  J Biochem Mol Toxicol       Date:  1999       Impact factor: 3.642

Review 4.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 5.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

Authors:  K Ito; T Iwatsubo; S Kanamitsu; K Ueda; H Suzuki; Y Sugiyama
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

6.  Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.

Authors:  C Merry; M G Barry; M Ryan; J F Tjia; M Hennessy; V A Eagling; F Mulcahy; D J Back
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

7.  Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

Authors:  R L Murphy; J P Sommadossi; M Lamson; D B Hall; M Myers; A Dusek
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

8.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

9.  Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.

Authors:  K T Olkkola; V J Palkama; P J Neuvonen
Journal:  Anesthesiology       Date:  1999-09       Impact factor: 7.892

10.  Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more
  1 in total

1.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.